GILD - Gilead Sciences, Inc.
65.16 +0.32 (0.49%)
Pre-Market: 6:05AM EST
| Previous Close | 65.12 |
| Open | 65.48 |
| Bid | 64.22 x 900 |
| Ask | 65.57 x 1400 |
| Day's Range | 64.30 - 66.74 |
| 52 Week Range | 64.27 - 89.54 |
| Volume | 705 |
| Avg. Volume | 7,106,396 |
| Market Cap | 83.878B |
| Beta (3Y Monthly) | 1.40 |
| PE Ratio (TTM) | 53.81 |
| EPS (TTM) | 1.21 |
| Earnings Date | Feb 4, 2019 - Feb 8, 2019 |
| Forward Dividend & Yield | 2.28 (3.48%) |
| Ex-Dividend Date | 2018-12-13 |
| 1y Target Est | 86.97 |
- Zacks•11 hours ago
Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod
Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.
- Zacks•16 hours ago
Evofem Shares Up as Birth Control Gel Succeeds in Phase III
Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birth control vaginal gel.
- Barrons.com•18 hours ago
Biotech Stocks Gilead Sciences and Biogen Have Room to Bounce Back
Big biotech stocks (GILD) (ticker: GILD) and (BIIB) (BIIB) were moving in opposite directions Tuesday, driven by analyst commentary. Where we were: It has been a difficult year for biotech stocks in general. Both Gilead and Biogen have notched losses larger than the broader market’s.
- Zacks•20 hours ago
Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer
Puma Biotech (PBYI) reports positive top-line data from the phase III NALA study, conducted on its breast cancer drug Nerlynx in third-line setting.
- Motley Fool•21 hours ago
What Happened With CAR-T Stocks in 2018
Here’s how CAR-T therapies did in their first full year on the market.
- Motley Fool•23 hours ago
3 Biotechs With Potential Blockbusters Near the Finish Line
Experimental new drugs at critical stages of development could soon send these stocks screaming in one direction or another.
- Zacks•2 days ago
Gilead Sciences (GILD) Stock Moves -0.69%: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $65.12, moving -0.69% from the previous trading session.
- InvestorPlace•2 days ago
5 Healthcare Stocks That Are Feeling Sick
Shares of Johnson & Johnson (NYSE:JNJ) have fallen below their 200-day moving average to return to levels not seen since August, down nearly 13% from the highs seen in early December. Analysts are looking for earnings of $1.95 per share on revenues of $20.2 billion. Gilead Sciences (NASDAQ:GILD) shares are down 16% from the highs set in early October, a double-top high that now sets up a possible violation of the May lows that would put the mid-2017 levels near $60 in play — which would be worth a 10% drop from current levels.
- InvestorPlace•2 days ago
7 Major Pharmaceutical Stocks to Quarantine Now
While millennials will soon overtake them in sheer number, boomers require extensive medical care. Theoretically, this trend should boost Big Pharma stocks. If pharmaceutical stocks represent viability, they’re doing a bad job of it.
Bloomberg•2 days agoGoldman Called 2019 ‘The Year of NASH,’ Others Say Not So Fast
While firms like Goldman Sachs have hailed 2019 as “the year of NASH” with late-stage data expected from Gilead Sciences Inc. and Intercept Pharmaceuticals Inc., other analysts say the first study results will only scratch the surface. “There’s part of the market that thinks 2019 is the year for NASH. NASH, or nonalcoholic steatohepatitis, is a significant form of chronic liver disease that affects both adults and children and can require a liver transplant.
- Motley Fool•3 days ago
2 Sets of Disasters Biotech Will Pay For in 2019
Here's how calamities we witnessed in 2018 will hound biotech investors in the new year.
- GuruFocus.com•4 days ago
Stocks That Fell to 3-Year Lows in the Week of Dec. 14
Gilead Sciences Inc., AT&T Inc., British American Tobacco PLC and Lloyds Banking Group PLC have declined to their respective 3-year lows
- Motley Fool•4 days ago
3 Biotechs Gilead Sciences Could Buy in March
With a new CEO from Roche on the way, these companies' odds of being acquired just rose a notch.
- Zacks•5 days ago
Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus
Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.
- Zacks•5 days ago
AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.
Investopedia•8 days ago7 Stocks That Can Lead The Market Long Term
- Zacks•5 days ago
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
- ACCESSWIRE•5 days ago
Today's Research Reports on Trending Tickers: Axovant Sciences and Gilead Sciences
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...
Zacks•6 days agoThe Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
- Zacks•6 days ago
Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals
Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.
- Zacks•7 days ago
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
A low key week for the biotech sector with focus on regular pipeline updates.
Zacks•7 days agoThe Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
- InvestorPlace•8 days ago
The 10 Best Marijuana Stocks to Buy in 2019
Despite their well-publicized fall from grace, several marijuana stocks have stabilized from their severe correction. Whether it’s political unrest in the Middle East, the spiraling protests in Paris or the ugly Huawei controversy, marijuana for now is mostly a North American issue. Second, medical cannabis potentially offers significant social utility.
- Zacks•8 days ago
Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
Gilead Sciences (GILD) names Roche's Daniel O'Day as the company's new Chairman and CEO.
Market Realist•8 days agoUnderstanding Seattle Genetics’ Operational Performance
How's Seattle Genetics Positioned? For fiscal 2018 and 2019, Seattle Genetics’ gross margins are expected at 88.54% and 88.58%, respectively, as compared with gross margins of 88.78% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at 85.83%, 84.81%, and 76.05%, respectively.
